{"success":true,"data":{"pressRelease":{"id":"50103","rtpr_id":"rest-5588a8b7207c499c","ticker":"IMMP","exchange":"NASDAQ","all_tickers":[],"title":"Pomerantz LLP Informs Shareholders of Class Action Filing Against Immutep Limited  – IMMP","author":"ACCESSWIRE","published_at":"2026-05-31T22:00:01.410Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May\n31, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed\nagainst Immutep Limited (\"Immutep\" or the \"Company\") (NASDAQ:IMMP).   Such\ninvestors are advised to contact Danielle Peyton at newaction@pomlaw.com or\n646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by\ne-mail are encouraged to include their mailing address, telephone number, and\nthe number of shares purchased.\n\nThe class action concerns whether Immutep and certain of its officers and/or\ndirectors have engaged in securities fraud or other unlawful business\npractices.\n\nYou have July 6, 2026, to ask the Court to appoint you as Lead Plaintiff for\nthe class if you purchased or otherwise acquired Immutep securities during the\nClass Period. A copy of the Complaint can be obtained at\nwww.pomerantzlaw.com.        \n\n[Click here for information about joining the class action]\n(https://pomlaw.com/cases-and-investigations/case-viewer/?company=IMMP)\n\nOn March 13, 2026, Immutep issued a press release \"announcing that the\nIndependent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study\nevaluating eftilagimod alfa (‘efti') in patients in 1(st) line non-small\ncell lung cancer has recommended the discontinuation of the trial following a\nplanned interim futility analysis in accordance with the study protocol.\"\nAccording to the press release, \"based on its review of the available safety\nand efficacy data, the IDMC recommended that the trial be discontinued for\nfutility\" and that, accordingly, \"enrolment in the study will be halted and\nthe Company will implement an orderly wind down of the study, including\nappropriate patient follow up and site close out in accordance with regulatory\nand ethical obligations.\"\n\nOn this news, Immutep's American Depositary Receipt (\"ADR\") price fell $2.27\nper ADR, or 82.44%, to close at $0.48 per ADR on March 13, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See www.pomlaw.com.\n\nAttorney advertising.  Prior results do not guarantee similar\noutcomes.  \n\nSOURCE: Pomerantz LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/pomerantz-llp-informs-shareholders-of-class-action-filing-agains-1164596)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"id":"rest-5588a8b7207c499c","title":"Pomerantz LLP Informs Shareholders of Class Action Filing Against Immutep Limited  – IMMP","author":"ACCESSWIRE","ticker":"IMMP","created":"2026-05-31T22:00:01.410Z","tickers":[],"exchange":"NASDAQ","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May\n31, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed\nagainst Immutep Limited (\"Immutep\" or the \"Company\") (NASDAQ:IMMP).   Such\ninvestors are advised to contact Danielle Peyton at newaction@pomlaw.com or\n646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by\ne-mail are encouraged to include their mailing address, telephone number, and\nthe number of shares purchased.\n\nThe class action concerns whether Immutep and certain of its officers and/or\ndirectors have engaged in securities fraud or other unlawful business\npractices.\n\nYou have July 6, 2026, to ask the Court to appoint you as Lead Plaintiff for\nthe class if you purchased or otherwise acquired Immutep securities during the\nClass Period. A copy of the Complaint can be obtained at\nwww.pomerantzlaw.com.        \n\n[Click here for information about joining the class action]\n(https://pomlaw.com/cases-and-investigations/case-viewer/?company=IMMP)\n\nOn March 13, 2026, Immutep issued a press release \"announcing that the\nIndependent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study\nevaluating eftilagimod alfa (‘efti') in patients in 1(st) line non-small\ncell lung cancer has recommended the discontinuation of the trial following a\nplanned interim futility analysis in accordance with the study protocol.\"\nAccording to the press release, \"based on its review of the available safety\nand efficacy data, the IDMC recommended that the trial be discontinued for\nfutility\" and that, accordingly, \"enrolment in the study will be halted and\nthe Company will implement an orderly wind down of the study, including\nappropriate patient follow up and site close out in accordance with regulatory\nand ethical obligations.\"\n\nOn this news, Immutep's American Depositary Receipt (\"ADR\") price fell $2.27\nper ADR, or 82.44%, to close at $0.48 per ADR on March 13, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See www.pomlaw.com.\n\nAttorney advertising.  Prior results do not guarantee similar\noutcomes.  \n\nSOURCE: Pomerantz LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/pomerantz-llp-informs-shareholders-of-class-action-filing-agains-1164596)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":""},"received_at":"2026-05-31T22:11:37.052Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/pomerantz-llp-informs-shareholders-of-class-action-filing-agains-1164596"},"analysis":{"id":"39534","press_release_id":"50103","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Pomerantz LLP issued a shareholder-solicitation notice naming Immutep Limited (IMMP); no new disclosure from the company itself.\n\nThe release is a routine lead-plaintiff-deadline reminder soliciting investors with losses to contact the firm on a contingency basis.\n\nThis is law-firm marketing, not an issuer disclosure or a court action; treat as low-signal noise.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"Pomerantz LLP announces that a class action lawsuit has been filed against Immutep Limited","namedEntities":{"people":[{"name":"Danielle Peyton","role":"Attorney/Contact"},{"name":"Abraham L. Pomerantz","role":"Founder (deceased)"}],"products":["eftilagimod alfa","efti"],"companies":[{"name":"Immutep Limited","ticker":"IMMP","relationship":"defendant"},{"name":"Pomerantz LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$2.27","context":"ADR price drop on March 13, 2026"},{"amount":"$0.48","context":"ADR closing price on March 13, 2026"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Pomerantz LLP. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"IMMP"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Pomerantz LLP issued a shareholder-solicitation notice naming Immutep Limited (IMMP); no new disclosure from the company itself.\n\nThe release is a routine lead-plaintiff-deadline reminder soliciting investors with losses to contact the firm on a contingency basis.\n\nThis is law-firm marketing, not an issuer disclosure or a court action; treat as low-signal noise.","key_figures":{},"named_entities":{"people":[{"name":"Danielle Peyton","role":"Attorney/Contact"},{"name":"Abraham L. Pomerantz","role":"Founder (deceased)"}],"products":["eftilagimod alfa","efti"],"companies":[{"name":"Immutep Limited","ticker":"IMMP","relationship":"defendant"},{"name":"Pomerantz LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$2.27","context":"ADR price drop on March 13, 2026"},{"amount":"$0.48","context":"ADR closing price on March 13, 2026"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-31T22:13:02.365Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":11899,"modelName":"george-droid-qwen-72b"}}